Ankyra Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2019-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.ankyratx.com
A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer
Phase 1
Not yet recruiting
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Drug: tolododekin alfa
- First Posted Date
- 2025-06-18
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- Ankyra Therapeutics, Inc
- Target Recruit Count
- 60
- Registration Number
- NCT07027514
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid TumorCutaneous TumorSubcutaneous TumorMalignant Solid TumorSolid TumorMetastatic Solid TumorMetastasis to Soft TissueNon Small Cell Lung CancerCutaneous Squamous Cell Carcinoma
- Interventions
- Drug: tolododekin alfa
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2025-02-12
- Lead Sponsor
- Ankyra Therapeutics, Inc
- Target Recruit Count
- 107
- Registration Number
- NCT06171750
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Providence Cancer Institute, Portland, Oregon, United States
🇺🇸Hillman Cancer Center, Pittsburgh, Pennsylvania, United States